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Leukocytes are the main cellular elements of inflammatory and immune reactions of the organism. Leukocyte alte-
rations are the consequence of an imbalance between the formation of leukocytes in the bone marrow and its elimi-
nation by the mononuclear phagocytic system. Factors that can modify leukopoyesis are varied and can lead to an 
alteration in the number of leukocytes or tumoral alterations of white cells (leukemias, lymphomas and plasma cell 
tumors). There is also a wide range of clinical manifestations that can derive from them: from very slight symptoms 
to life-threatening conditions. In some cases oral manifestations will be the first signs and it will be the dentist’s res-
ponsibility to identify the underlying disorder and guide the diagnosis of the patient.  It is important to be familiar 
with the special management required for these patients, in which the dental treatment can affect the course of the 
underlying disease. The objective of this article is to review the literature concerning the oral manifestations and 
the considerations that must factor in the dental treatment of patients with leukocyte alterations. 
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Introduction
Leukocytes are formed in the bone marrow and then 
transported by the blood to different tissues. Normal 
counts of leukocytes in blood are 4.500-10.000 cells/
mm3.
Leukocyte alterations are the consequence of an imba-
lance between their formation in the bone marrow and 
subsequent elimination by the mononuclear phagocytic 
system. 
Factors that can modify leukopoyesis are varied and can 
lead to an alteration in the number of leukocytes or tu-
moral alterations of white cells (leukemias, lymphomas 
and plasma cell tumors). There is also a wide range of 
clinical manifestations that can derive from them: from 
very slight symptoms to life threatening conditions. In 
some cases oral manifestations will be the first signs and 
it will be responsibility of the dentist to identify that an 
underlying disorder is present and to guide the diagnosis 
of the patient; in the case of patients already diagnosed, 
special considerations will be required to manage the-
se patients, in which the dental treatment can affect the 
course of the underlying disease.  
Objectives
The aim of this article is to carry out a review of literatu-
re about leukocyte alterations, and to examine the latest 
research concerning the oral manifestations and dental 
management of patients with the associated conditions.
Material and Methods
The subject-related research was carried out on the 
Pubmed-Medline database. As a research strategy we 
employed different combinations of the following key 
words: oral complications, oral manifestations, dental 
management, agranulocytosis, neutropenia, leukocyto-
sis, hematologic malignancies, lymphoma, leukemia, 
mieloma. 
We included articles published in both English and Spa-
nish, dating from 1995. We reviewed 21 articles. 
Results
ALTERATIONS IN THE NUMBER OR FUNCTION 
OF LEUCOCYTES
1. Leukopenia 
Leukopenia is a decrease in the total number of leuko-
cytes under 4.000 - 4.500/mm³. However, even though 
leukopenias can be associated with a global decrease in 
leukocytes, they are usually caused by an impaired capa-
city to generate neutrophils. 
Neutropenia is defined as a total circulating neutrophil 
count lower than 2000x106/litre (1). It is not a disease 
but a sign of an underlying disorder with a wide range 
of underlying causes. Decreased production of neutro-
phils is associated with deficiencies of vitamin B12 and 
folic acid, aplastic anemia, tumors (leukemia, solid tu-
mors that invade bone marrow), drugs, metabolic disea-
ses (glycogen storage disease type 1b, methylomalonic 
acidaemia), nutritional deficiencies (malnutrition,cop-
per deficiency), radiation injury, immune mechanisms, 
and heritable genetic aberrations (congenital neutro-
penia, cyclic neutropenia). Certain infections decrease 
the number of neutrophils in the circulating blood due 
to increased migration of neutrophils into the tissue, se-
questration of neutrophils, or direct toxic effect of the 
microorganism and its toxins on the bone marrow (2).
Neutropenias that can cause oral manifestations:
In general, the most common oral complications related 
to neutropenia are ulcers, severe gingivitis and perio-
dontitis (1). 
Acquired agranulocytosis or neutropenia is far more 
common than congenital forms, often accompanying 
viral infections, or it may be attributable to drugs in > 
70% of cases, which is a rare and potentially life-threa-
tening condition, owing to either myelosuppression or 
antibody-mediated destruction. Drugs associated with 
agranulocytosis include antiepileptics, antithyroid drugs 
(carbimazole, methimazole, and propylthiouracil), anti-
biotics (penicillin, chloramphenicol, and cotrimoxazo-
le), cytotoxic drugs, gold, nonsteroidal antiinflammatory 
drugs (indomethacin, naproxen, and phenylbutazone), 
mebendazole, the antidepressant mirtazapine, and some 
antipsychotics (clozapine) (2). Also metamizole, a drug 
frequently prescribed by dentists, may cause agranulo-
cytosis (3).
In the oral cavity, agranulocytosis can appear as necrotic 
ulcers with a white or greyish surface without signs of 
inflammation (2,3).
The mortality rate for agranulocytosis is 7 to 10%. For 
therapy, it is essential to stop the drug. To reduce the time 
required to normalize granulopoiesis from 1-2 weeks to 
a few days, the application of granulocyte growth factor 
(G-CSF) or granulocyte transfusion and the use of broad 
spectrum antibiotics to protect bacterial infections are 
recommended (3). 
Severe congenital neutropenia or Kostmann’s syndrome 
is characterized by severe neutropenia (<500 cellsx106/
litre), recurrent bacterial infections and failure in the 
maturation from promielocytes into mielocytes. At first 
it was classified as a recessive autosomal disease, but 
the underlying mutation has not been found yet (1). Oral 
problems include painful aphthous ulcers and gingivitis, 
and despite thorough dental care, children with conge-
nital neutropenia tend to develop severe periodontal di-
sease early in life. Although treatment with G-CSF has 
improved the control of bacterial infections, including 
gingivitis and peridontitis, many patients still experien-
ce periodontal disease, despite normal neutrophil counts 
(4). 
Benign congenital neutropenia includes several benign 
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rrow, can commonly limit the infection to the lymphatic 
nodes and the liver, systemic involvement being infre-
quent (1).
In patients with lazy leukocyte syndrome stomatitis, 
gingivitis, and recurrent ulcerations have been reported 
(6). 
Paediatric patients with neutrophil functional alterations 
such as chronic granulomatous disease and Chédiak-Hi-
gashi syndrome often suffer from mucous ulcerations, re-
current sinusitis, cervical lymphadenitis and candidiasis. 
Prepuberal periodontitis has been related to a leucocyte 
adhesion deficiency (1,6) and generalized pre-puberal 
periodontitis, with neutrophil chemotaxis defects (1).
Dental management of patient with neutrophil altera-
tions
Preventive measures and control of intraoral infectious 
processes, to minimize the necessity of surgical treatment, 
must be a constant factor in the dental treatment of these 
patients. Conventional preventive measures such as the 
use of topic fluoride, fissure sealants, dietary advice and 
the promotion of oral health, become especially impor-
tant. It has been proven that the periodic removal (mon-
thly) of plaque and calculus as well as the use of an-
tiseptics (clorhexidine 0.2%) and periodontal treatment 
in patients with cyclic neutropenia and Kostmann’s syn-
drome help to mantain the periodontal insertion. Never-
theless, other patients with neutrophil dysfunction suffer 
unavoidably from periodontitis and dental mobility even 
with adequate care. As a consequence, periodontal sur-
gery started to be considered only recently (1). 
When oral surgical procedures are anticipated, a platelet 
count of ≥50,000 cells/µL, absolute neutrophil count of 
≥500 cells/µL, and hemoglobin concentration of ≥7 g/
dL, are recommended to comfortably assure effective 
hemostasis and reduce the risk of postoperative bacterial 
infection (2). Other prophylactic measures to minimize 
the bacteraemia risk are: antiseptic rinse with clorhexi-
dine prior to any dental treatment, antibiotic administra-
tion before and after surgery and the primary closing of 
the surgical wound (1).
Considerations in dental management of patients with 
neutrophil disorders are summarised in table 1.
disorders. They present scarce and generally mild mu-
cocutaneous infections. Neutropenia usually becomes 
chronic although spontaneous remissions during child-
hood have been described. In any case, treatment is not 
needed (1). Several case reports have been published 
describing periodontitis as a manifestation of chronic 
neutropenia (5). 
Cyclic neutropenia is characterized by a very severe neu-
tropenia (<200 cells x 106/litre) lasting from 3 to 6 days 
every 21 days, although in some cases the hematopoiesis 
cycles can vary from 2 to 5 weeks. It can be asymp-
tomatic except in the neutropenic stage when aphthous 
ulcers, gingivitis, stomatitis and cellulitis appear (1).
2. Neutrophil functional alterations 
Neutrophil dysfunctions are usually associated with he-
reditary intrinsic cell defects, although sometimes they 
are a consequence of extrinsic etiological factors such as 
prescription drugs, diabetes and certain infections.
Infections in patients with alterations in neutrophil 
function possess clinical characteristics that are condi-
tioned by the kind of functional alteration. 
In patients with leukocyte adhesion defects, the lesions 
have less pus and are formed by necrotic tissues with 
few inflammatory components. 
By contrast, in the case of defects in the neutrophil mi-
gration the abscesses present abundant cells (neutrophils 
and macrophages), presumably due to the late arrival of 
neutrophils to the infected area.
In patients who suffer from a decrease in the neutrophil 
bactericide activity, as in the case of chronic granuloma-
tous disease, abscesses are spread out, affect deep levels 
and have granulomas with or without purulent material. 
The skin and the affected tissues typically present pustu-
les with a scarce inflammatory component.  
Infections in patients who present alterations in the neu-
trophil function are often the consequence of common 
microorganisms in skin and mucous membranes such 
as Staphylococcus aureus, Pseudomonas, Candida spp. 
and Aspergillus spp. These patients, unlike neutropenic 
patients who suffer from bacteraemias and the dissemi-
nation of infections in deep tissues such as the bone ma-
Considerations in dental management of patients with neutrophil disorders.
In all patients In oral surgery
- Application of topic fluoride and fissure sealants.
- Dietary advice and promotion of oral health 
- Antiseptic rinse with clorhexidine previous to any 
dental treatment 
- Observe acceptable counts of platelets, neutrophils 
and hemoglobin concentration.  
- Antibiotic administration before and after surgery 
- Primary closing of the surgical wound.
Table 1. Considerations in dental management of patients with neutrophil disorders.
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Leukocytosis
Leukocytosis is an increase in the number of leukocytes 
in the blood. We say that there is leukocytosis when the 
white blood cells count is higher than 10.000/mm³.
Leukocytosis, like neutropenia, is not a disease itself, 
but the sign of an underlying disorder of variable etiolo-
gy. It is a common laboratory finding, often due to rela-
tively benign conditions, as the normal reaction of bone 
marrow to infection or inflammation leads to an increase 
in the number of white blood cells, predominantly po-
lymorphonuclear leukocytes and less mature cell forms 
(the “left shift”). Other causes, much less common but 
more serious, include primary bone marrow disorders. 
Physical stress and emotional stress can also elevate 
white blood cells counts. Drugs commonly associated 
with leukocytosis include corticosteroids, lithium and 
beta agonists. Increased eosinophil or basophil counts, 
resulting from a variety of infections, allergic reactions 
and other causes, can lead to leukocytosis in some pa-
tients (7).
Dental management of patient with leukocytosis
Dental treatment of patients with leukocytosis dont’t 
need special considerations apart of ruling out oral pa-
thology that could have caused leucocyte increase, and 
if found treat it as established. If we don’t find any pa-
thology that could increase the white cells count it is re-
commended to refer the patient to the specialist in order 
to rule out other diseases.  
HEMATOLOGIC MALIGNANCIES OF WHITE 
CELLS 
There are three main groups of hematologic malignan-
cies: leukemia, lymphoma and plasma cell tumors. Leu-
kemias are derived from hematopoyetic cells that proli-
ferate initially in the bone marrow before spreading to 
peripheral blood, spleen, lymphatic nodes and, finally, to 
other tissues; they differ from lymphomas because the-
se arise first in lymphatic nodes, however they can also 
spread to blood and bone marrow. Plasma cell tumors 
are lymphoid neoplastic proliferations of B cells.
1. Leukemia
Leukemia results from the proliferation of a clone of 
abnormal hematopoietic cells with impaired differentia-
tion, regulation, and programmed cell death (apoptosis). 
Leukemic cell multiplication at the expense of normal 
hematopoietic cell lines causes marrow failure, depres-
sed blood cell count (cytopenia), and death as a result of 
infection, bleeding, or both (8). 
Leukemia is classified according to the primary hema-
topoietic cell affected (myeloid or lymphoid) and by the 
acute or chronic behavior (8,9).
Chronic leukemia, with a less pronounced marrow fa-
ilure, has an indolent course that usually lasts several 
years.
Acute leukemia is usually precipitous, with bone marrow 
failure and associated anemia, infection, and bleeding. 
Symptoms are generally flu-like with bone pain, joint 
pain, or both, caused by malignant marrow expansion. 
Thrombocytopenia is manifested by petechial skin and 
posterior palate hemorrhages and gingival bleeding. 
Acute myelogeous leukemia symptoms include fever, 
fatigue, pallor, mucosal bleeding, petechiae, and local 
infections; clinical manifestations of acute lymphocytic 
leukemia are similar to those of acute myelogeous leu-
kemia, but with a high incidence of central nervous sys-
tem disease (8).
Gingival hyperplasia secondary to infiltration of the gin-
gival tissue with leukemia cells is thoroughly described 
in the literature (8-11). It is characterized by progressi-
ve enlargement of the interdental papillae as well as the 
marginal and attached gingival. In the condition’s most 
pronounced form, the crowns of the teeth may be co-
vered. Gingiva appear swollen, devoid of stippling and 
pale red to deep purple in colour (8). Gingival infiltra-
tion by leukemic cells will also predispose the patient 
with leukemia to bleeding (10). Gingival hiperplasia 
is more common in acute tan chronic leukemia (8,10), 
nonetheless, the development of gingival infiltration is 
unpredictable in any individual patient. Generally, gin-
gival hyperplasia resolves completely or at least partly 
with effective leukemia chemotherapy (10).
Gingival ulcerations may occur as a result of infection 
by normal oral flora in the setting of neutropenia (8).
2. Lymphomas
Lymphomas are a diverse group of neoplasms affecting 
the lymphoreticular system. Lymphomas have been 
traditionally divided into Hodgkin’s disease and non 
Hodgkin’s disease.  Hodgkin’s disease is characterized 
histologically by presence of multi-nucleated Reed-Ster-
nberg cells. All other neoplasms of the lymphoid system 
are referred to as Non-Hodgkin’s lymphoma and are 
derived predominantly from the cells of B-lymphocyte 
series (12). These diseases differ in a number of key cli-
nical aspects (13).
Hodgkin lymphoma (HL) most frequently presents as 
cervical lymphadenopathy and rarely involves extrano-
dal sites (12,13).  LH spreads in a predictable manner 
along lymphatic channels from one involved lymph 
node group to contiguous lymph nodes; because of this 
pattern of spread, limited HL is more amenable to cure 
with radiotherapy. The seldomly reported lesions include 
different locations: palate, tonsil, floor of mouth, buccal 
alveolar mucosa, buccal vestibule, and mandibular bone, 
with no one site accounting for a predominance of cases. 
The more commonly described clinical presentations are 
ulcerations and swellings (13).
Non-Hodgkin lymphoma (NHL) manifests up to 40% of 
the time at an extra nodal site.  Moreover, 2-3% of these 
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extra nodal cases may arise primarily in the oral cavi-
ty and jaws (12). Nonetheless, NHL is the second most 
common oropharingeal malignancy after squamous cell 
carcinoma. Waldeyer’s ring is most commonly involved, 
although any site may be affected (14). Oral lesions may 
appear as an erythematous, painless enlargement, often 
with surface ulceration secondary to trauma (14, 15), 
but rarely with deep oral ulceration (14). Jaw involve-
ment by NHL is rare, but among jaw lesions, maxilla is 
more frequently involved than mandible (12). Radiogra-
phic findings may include diffuse bone destruction, and 
loss of the lamina dura. It is commonly associated with 
teeth loosening, and paresthesia, hardly ever being ac-
companied by “B symptoms”: fever of unknown origin 
(>38ºC), unexplained weight loss (>10% over 6 mon-
ths), drenching night sweats, visceral pain and malaise 
(14,15).
3. Plasma cell neoplasia 
Plasma cell tumors are lymphoid neoplastic prolife-
rations of B cells that may develop in a disseminated 
manner, affecting several bones (multiple myeloma) or 
less commonly as a solitary lesion at any interbone site 
(solitary bone plasmacytoma) or in soft tissues (extra-
medullary plasmacytoma). 
In 12-15% of multiple myeloma (MM) cases, the onset 
of this process is determined by oral symptoms, being 
the most common toothache, oral or facial pain and de-
viations of the mandible. Bone lesions in MM are visi-
ble radiographically as well-defined, solitary or multi-
ple radiolucent areas, without peripheral reinforcement, 
showing a tendency to converge and present images with 
septa or in “soap bubbles”. 
Solitary bone plasmacytoma rarely affects the oral cavi-
ty, but when it does, it shows a predilection for the retro-
molar area of the mandible. Its radiological appearance 
may have one of two patterns, as either an oval-shaped 
lytic image with destruction of the cortical bone, or as 
a hyperinsufflating lesion showing a convex bicortical 
bone.
Extramedullary plasmacytoma may be found in any part 
of the body having lymphoid tissue. In 90% of the cases 
this disease develops in the head and neck, showing a 
preference for the upper respiratory and digestive tracts. 
Clinically, they appear as a sessile or pediculated out-
growth, either circumscribed or infiltrating. There are no 
specific clinical manifestations as symptoms and they 
depend on the location of the tumor (16).
Dental management of patient with hematologic malig-
nancies. 
Patients in long-term remission can undergo dental 
treatment, while patients with advanced or relapsed di-
sease with reserved prognosis should receive palliative 
or urgent treatment only. Dental treatment should be per-
formed always after consultation with the specialist, as it 
can be modified by certain aspects of the therapy and of 
the disease prognosis (17).
It is very important to carry out a detailed history. This 
should include the diagnosis and status of the neopla-
sia, the nature and duration of previous and ongoing 
treatment, prognosis, comorbid medical conditions, cu-
rrent medications, past dental history, and prior history 
of oral and nonoral infections (14).
All patients with hematologic malignancies should 
undergo comprehensive oral and dental evaluation in 
which is important to:
- Evaluate for presence of petechiae, ecchymosis, gingi-
val hemorrhage, tooth mobility, tooth migration, facial 
pain, and/or parestesia, indicative of local manifesta-
tions of hematologic malignancies. 
- Evaluate for presence of dental/periodontal disease as a 
risk factor for development of osteonecrosis of the jaw 
(ONJ) and/or bacteriemia. 
- Evaluate radiographs (panoramic and periapicals, as 
indicated) for evidence of osteolytic lesions (if detec-
ted, refer for further radiographic evaluation) and to 
determine potential risk for developing ONJ (17).
Dental treatment of these patients should be performed 
before starting the chemo/radiotherapy, treating any 
teeth with pulpal and periapical pathology, periodontal 
abscess, pericoronaritis, gross clinical caries and pe-
riodondontal disease. In the case of patients scheduled 
for autologous hematopoietic cell transplant, dental 
treatment should be avoided during the 3 days when 
stem cells are mobilized and harvested to minimize con-
tamination secondary to iatrogenic transient bacteremia 
(14).
The main problems in dental treatment of patients with 
hematologic malignancies of white cells are: 
1. Tendency to bleed:
Intraoral bleeding is commonly observed, manifes-• 
ting with petechiae and ecchymoses, and occasiona-
lly hematoma formation. These lesions do not require 
treatment, and large hematomas should not be exci-
sed due to risk of hemorrhage. 
For routine operative care where bleeding is not anti-• 
cipated, treatment can generally be provided in even 
severely thrombocytopenic patients without the need 
for transfusions. Depending on the extent of surgery, 
coordination of platelet transfusion the day of the 
procedure may be indicated, although single tooth 
extractions can generally be managed by an expe-
rienced clinician with localized measures even with 
levels as low as 15,000 cells/mL (14).
2. Increased risk of infection: 
Patients with compromised lymphocyte function or low 
neutrophil count due to their malignancy or secondary 
to myelosuppressive chemotherapy are prone to newly 
acquired infections and/or exacerbation or reactivation 
of latent infections (14,18,19). In many cases the clinical 
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presentation of oral infections may be atypical compared 
to what would normally be expected in a healthy patient 
population. Use of diagnostic tools, including cultures, 
cytological smears, and tissue biopsies, is critical in 
identifying pathogens and guiding appropriate therapies 
(14).
 a) Odontogenic infections: 
Oral prophylaxis, oral hygiene instruction and elimina-
tion of oral sources of infection before beginning cancer 
treatment, can significantly reduce the risk of infectious 
complications (14, 19). Odontogenic infections of pul-
pal and periodontal origin are frequently encountered 
and should be suspected in the presence of orofacial 
pain, large restorations, gross clinical caries, and peria-
pical radiolucency. Dental radiographs must be obtained 
for any suspected odontogenic infection. Endodontically 
treated teeth with a radiographically adequate seal can 
become symptomatic during severe neutropenia, and 
while these may be initially managed with antibiotics, in 
most cases extraction is indicated. Similarly, chronic pe-
riodontal disease can become acutely exacerbated with 
or without the traditional clinical signs of inflammation 
and swelling. Treatment includes broad-spectrum anti-
biotics, chlorhexidine rinses, scaling and curettage, and 
extraction of hopeless teeth. Extractions should be per-
formed as early as possible prior to beginning therapy 
to allow maximum healing. Prior to extractions or any 
other invasive procedures the platelet and absolute neu-
trophils counts must be reviewed and appropriate mea-
sures taken to minimize risk of complications (14).
 b) Opportunistic infections: 
Viral infections: primary infection or reactivation of • 
herpes family viruses is common in these patients, 
especially during intensive chemotherapy and in the 
context of advanced disease. Herpex simplex virus is 
the most common viral infection in these patients and 
typically presents as single or multiple painful ulce-
rative lesions that may involve any oral mucosal sur-
face. Varicella-zoster virus (VZV) reactivation is less 
common. Treatments for both infections include acy-
clovir, valacyclovir or famciclovir, the latter appea-
ring to have an advantage in preventing post-herpetic 
neuralgia following VZV infections (14,19). 
Fungal infections: oropharingeal candidiasis is the • 
most common fungal infection in cancer patients. 
Candidiasis can present as pseudomembranous (the 
most common), erythematous, hyperplastic, or an-
gular cheilitis. Symptoms include generalized dis-
comfort, dysgeusia, xerostomia, and burning. Initial 
episodes can be treated with topical azoles or nystatin 
for 7 to 14 days; in severe cases, systemic therapy 
should be considered with 100 to 200 mg/day of flu-
conazole or itraconazole for 7 to 14 days or long-term 
for prophylaxis, especially in recurrent cases. In pa-
tients with nonhealing solitary ulcerations, deep fun-
gal infections (aspergillus, zygomyces, and histoplas-
ma) should be considered, the management of which 
requires aggressive therapy with intravenous azoles, 
amphotericin B, and the echinocandins (14,19).
3. Risk of developing ONJ: in patients treated with ra-
diotherapy or intravenous bisphosphonates there is a 
risk of developing osteonecrosis and it is recommended 
to follow the corresponding protocols. 
4. Anemia
Patients with severe anemia often complain of that • 
they fatigue easily and may not be able to tolerate 
time-consuming dental treatment. 
The need for blood products and the appropriate ve-• 
nue for dental treatment should be discussed with the 
patient’s oncologist, as these patients may require 
continuous monitoring of vital signs and blood counts 
perioperatively (17).
5. Corticosteroids treatment: patients receiving high-do-
se systemic corticosteroids may display evidence of se-
condary adrenal insufficiency. Adrenal crises secondary 
to insufficiency are rare in the dental setting, and steroid 
supplementation before nonsurgical dental procedures is 
not recommended. Steroid supplementation before oral 
surgery is usually recommended. The amount, duration, 
and venue for supplementation should be determined by 
both the dental specialist performing the procedure and 
the patient’s oncologist (17).
6. Secondary malignancy: patients treated for hemato-
logic malignancies are at high risk for relapse of pri-
mary disease as well as developing second hematologic 
and solid malignancies. Considering the increased risk 
of second primary cancer of the head and neck in the 
survivors of leukemia and lymphoma, and the fact that 
squamous cell carcinoma is the most common second 
primary solid malignancy after allogeneic hematopoye-
tic cell transplant, oral health care professionals play a 
critical role in the long-term surveillance of this patient 
population (14).
7. Specific considerations:
- Patients with renal dysfunction may require modified 
dosing intervals of medications (17).
- In patients with multiple myeloma, it is important to 
evaluate for presence of hard/soft tissue masses that 
could indicate deposition of plasma cells and/or light-
chain associated amyloid, and biopsy if necessary 
(17).
- Patients with multiple myeloma and significant bone 
pain, especially in the back, may need frequent breaks 
and may require frequent repositioning during dental 
procedures (17).
- In patients undergoing orthodontic treatment, the re-
moval of orthodontic appliances and delivery of re-
tainers is recommended, as well as the postponement 
of orthodontic treatment until the patient has finished 
immunosuppressive therapy and the risk of hemato-
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logic relapse requiring further intervention is reduced 
(20,21). 
Considerations in dental treatment of patients with he-
matologic malignancies are summarized in table 2.
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Considerations in dental management of patients with hematologic malignancies
Prior to dental treatment During dental treatment
1. Patients in long-term remission can undergo dental 
treatment, while patients with advanced or relapsed disease 
with reserved prognosis should receive palliative or urgent 
treatment only.
2. Dental treatment should be performed always after 
consultation with the specialist
3. It is important to carry out a detailed history, a comprehensive 
oral and dental evaluation and a complete radiographic exam. 
4. Dental treatment should be performed before starting the 
chemo/radiotherapy.
Bleeding tendency 1. 
Increased risk of infection.2. 
Risk of developing 3. 
osteonecrosis of the jaw. 
Anemia 4. 
Corticosteroids treatment.5. 
Secondary malignancies. 6. 
Specific considerations. 7. 
Table 2. Considerations in dental management of patients with hematologic malignancies
